Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial canceR
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5503 Authors: David S. Miller, Giovanni Scambia,...
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5509 Authors: Lukas Rob, Peter Mallmann, Pawel...
A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5501 Authors: Robert L. Coleman, Danielle Enserro,...
Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5500 Authors: Takashi Onda, Toyomi Satoh, Toshiaki...
Správa z ASCO 2018 – Gynekologické malignity
23 septembra, 2020 4:53 pmAj keď sa tohtoročné ASCO nieslo v znamení noviniek a zmien v liečbe pediatrických, pľúcnych, prsníkových a pankreatických karcinómov, boli prezentované niektoré práce z gynekologickej...
A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: 9025 Authors: Jonathan Wade Goldman,...
4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: 9030 Authors: Enriqueta Felip, Matthew...
Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: 9006 Authors: Naoki Furuya, Tatsuro...
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: LBA4 Authors: Gilberto Lopes, Yi-Long...
Pembrolizumab Improves Survival, Reduces Toxicity Over Chemotherapy in Low PD-L1–Expressing NSCLC
23 septembra, 2020 4:52 pmJune 4, 2018 Pembrolizumab significantly improved overall survival (OS) compared with platinum-based chemotherapy as first-line therapy for patients with...